These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 30328533)

  • 1. Clinical significance of intratumoral HER2 heterogeneity on trastuzumab efficacy using endoscopic biopsy specimens in patients with advanced HER2 positive gastric cancer.
    Yagi S; Wakatsuki T; Yamamoto N; Chin K; Takahari D; Ogura M; Ichimura T; Nakayama I; Osumi H; Shinozaki E; Suenaga M; Fujisaki J; Ishikawa Y; Yamaguchi K; Namikawa K; Horiuchi Y
    Gastric Cancer; 2019 May; 22(3):518-525. PubMed ID: 30328533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer.
    Wakatsuki T; Yamamoto N; Sano T; Chin K; Kawachi H; Takahari D; Ogura M; Ichimura T; Nakayama I; Osumi H; Matsushima T; Suenaga M; Shinozaki E; Hiki N; Ishikawa Y; Yamaguchi K
    J Gastroenterol; 2018 Nov; 53(11):1186-1195. PubMed ID: 29633013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Poor efficacy response to trastuzumab therapy in advanced gastric cancer with homogeneous HER2 positive and non-intestinal type.
    Xu C; Liu Y; Jiang D; Li Q; Ge X; Zhang Y; Huang J; Su J; Ji Y; Hou J; Lu S; Hou Y; Liu T
    Oncotarget; 2017 May; 8(20):33185-33196. PubMed ID: 28388541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive factors of trastuzumab-based chemotherapy in HER2 positive advanced gastric cancer: a single-center prospective observational study.
    Li Q; Li H; Jiang H; Feng Y; Cui Y; Wang Y; Ji Y; Yu Y; Li W; Xu C; Yu S; Zhuang R; Liu T
    Clin Transl Oncol; 2018 Jun; 20(6):695-702. PubMed ID: 29168107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Late stage gastric cancer patients with extra gained HER2 positivity by dual block assessment may not show compromised efficacy to trastuzumab treatment.
    Xu C; Liu Y; Jiang D; Ge X; Huang J; Su J; Zhang X; Lu S; Ji Y; Hou J; Liu T; Hou Y
    Aging (Albany NY); 2019 Nov; 11(22):10052-10060. PubMed ID: 31739285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: results of the GASTric cancer HER2 reassessment study 3 (GASTHER3).
    Seo S; Ryu MH; Park YS; Ahn JY; Park Y; Park SR; Ryoo BY; Lee GH; Jung HY; Kang YK
    Gastric Cancer; 2019 May; 22(3):527-535. PubMed ID: 30386954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival analysis based on human epidermal growth factor 2 status in stage II-III gastric cancer.
    Cho JH; Lim JY; Cho JY
    World J Gastroenterol; 2017 Nov; 23(41):7407-7414. PubMed ID: 29151694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased assessment of HER2 in metastatic gastroesophageal cancer patients: a nationwide population-based cohort study.
    Dijksterhuis WPM; Verhoeven RHA; Meijer SL; Slingerland M; Haj Mohammad N; de Vos-Geelen J; Beerepoot LV; van Voorthuizen T; Creemers GJ; van Oijen MGH; van Laarhoven HWM
    Gastric Cancer; 2020 Jul; 23(4):579-590. PubMed ID: 31927675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive Roles of HER2 Gene Amplification and Neutrophil-to-Lymphocyte Ratio on Survival in HER2-Positive Advanced Gastric Cancer Treated With Trastuzumab-Based Chemotherapy.
    Park JH; Yeo JH; Kim YS; Park I; Ahn HK; Shin DB; Lee WK; Yang JY; Kim HS; Sym SJ
    Am J Clin Oncol; 2021 Jun; 44(6):232-238. PubMed ID: 33710139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective observational study on the optimal maintenance strategy in HER2-positive advanced gastric cancer treated with trastuzumab-based therapy.
    Li Q; Lv M; Jiang H; Wang Y; Yu S; Li W; Yu Y; Liu T
    J Cancer Res Clin Oncol; 2020 Jan; 146(1):287-295. PubMed ID: 31667572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Retrospective Analysis for Patients with HER2-Positive Gastric Cancer Who Were Treated with Trastuzumab-Based Chemotherapy: In the Perspectives of Ethnicity and Histology.
    Yi JH; Kang JH; Hwang IG; Ahn HK; Baek HJ; Lee SI; Lim DH; Won YW; Ji JH; Kim HS; Rha SY; Oh SY; Lee KE; Lim T; Maeng CH; Kim MJ; Kim ST; Lee J; Park JO; Park YS; Lim HY; Kang WK; Park SH
    Cancer Res Treat; 2016 Apr; 48(2):553-60. PubMed ID: 26323641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HER2 Expression, Test Deviations, and Their Impact on Survival in Metastatic Gastric Cancer: Results From the Prospective Multicenter VARIANZ Study.
    Haffner I; Schierle K; Raimúndez E; Geier B; Maier D; Hasenauer J; Luber B; Walch A; Kolbe K; Riera Knorrenschild J; Kretzschmar A; Rau B; Fischer von Weikersthal L; Ahlborn M; Siegler G; Fuxius S; Decker T; Wittekind C; Lordick F
    J Clin Oncol; 2021 May; 39(13):1468-1478. PubMed ID: 33764808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HER2 heterogeneity is a poor prognosticator for HER2-positive gastric cancer.
    Kaito A; Kuwata T; Tokunaga M; Shitara K; Sato R; Akimoto T; Kinoshita T
    World J Clin Cases; 2019 Aug; 7(15):1964-1977. PubMed ID: 31423428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trastuzumab Specific Epitope Evaluation as a Predictive and Prognostic Biomarker in Gastric Cancer Patients.
    Koh J; Nam SK; Lee YW; Kim JW; Lee KW; Ock CY; Oh DY; Ahn SH; Kim HH; Kang KW; Kim WH; Lee HY; Lee HS
    Biomolecules; 2019 Nov; 9(12):. PubMed ID: 31779184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Depth of response predicts the clinical outcome of advanced HER2-positive gastric cancer to trastuzumab-based first-line chemotherapy.
    Kadowaki S; Masuishi T; Eto T; Narita Y; Taniguchi H; Ura T; Ando M; Tajika M; Niwa Y; Yatabe Y; Muro K
    Cancer Chemother Pharmacol; 2017 Oct; 80(4):807-813. PubMed ID: 28821938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of Trastuzumab Biosimilar (CT-P6) Compared With Reference Trastuzumab in Patients With HER2-positive Advanced Gastric Cancer: A Retrospective Analysis.
    Park JH; Yeo JH; Kim YS; Park I; Ahn HK; Cho EK; Shin DB; Yang JY; Kim HS; Lee WK; Sym SJ
    Am J Clin Oncol; 2022 Feb; 45(2):61-65. PubMed ID: 34991106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer.
    Müller V; Clemens M; Jassem J; Al-Sakaff N; Auclair P; Nüesch E; Holloway D; Shing M; Bang YJ
    BMC Cancer; 2018 Mar; 18(1):295. PubMed ID: 29544445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive value of serum HER2 ECD in patients with HER2-positive advanced gastric cancer treated with trastuzumab plus chemotherapy.
    Zhou J; Peng Z; Liu Y; Gong J; Zhang X; Lu M; Gao J; Li Y; Li Y; Shen L
    J Gastroenterol; 2015 Sep; 50(9):955-61. PubMed ID: 25702260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor Heterogeneity in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer Assessed by CT Texture Analysis: Association with Survival after Trastuzumab Treatment.
    Yoon SH; Kim YH; Lee YJ; Park J; Kim JW; Lee HS; Kim B
    PLoS One; 2016; 11(8):e0161278. PubMed ID: 27517841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum level of hepatocyte growth factor is a novel marker of predicting the outcome and resistance to the treatment with trastuzumab in HER2-positive patients with metastatic gastric cancer.
    Takahashi N; Furuta K; Taniguchi H; Sasaki Y; Shoji H; Honma Y; Iwasa S; Okita N; Takashima A; Kato K; Hamaguchi T; Shimada Y; Yamada Y
    Oncotarget; 2016 Jan; 7(4):4925-38. PubMed ID: 26716644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.